Partial Opioid Agonist·Analgesia - Opioids

Buprenorphine patch

Moderate to severe chronic pain unresponsive to non-opioids

S8Authority requiredPBSOPIOIDNorspan+2

No source link confirmed for this record yet. Its own source notes are under Additional.

At a glance

Max Dose

40 mcg/hr

Duration

7 DAYS

Caution: Heat Tox

HIGH RISK

Renal Safe

YES

Cautions

Avoid / Cautions

Acute pain, post-operative pain, opioid-naive patients needing immediate relief. Pregnancy Category C.

Where it stands

Rapid Summary

Overview

Transdermal partial mu-opioid agonist. Provides a highly stable, 7-day continuous release of analgesia. Exceptional safety profile regarding respiratory depression and renal failure.

Clinical Focus

Heat drastically accelerates absorption. A hot bath or heat pack over the patch can dump a fatal dose into the blood.

Bottom Line

Buprenorphine patch is a transdermal partial opioid agonist for chronic pain with ceiling effect on respiratory depression, but takes 12-24 hours to reach steady state and complicates acute pain management.

Formulation & Access

Brand Names

Norspan

Parenteral

Transdermal Patches (5, 10, 15, 20 mcg/hour).

Prescribing & PBS

Highly Restricted (S8). Authority Required (PBS).

Indications & Use

Primary

PBSTGA

Moderate to severe chronic pain unresponsive to non-opioids.

Clinical Place

Superb first-line baseline opioid for frail elderly patients with chronic pain, due to the 'ceiling effect' on breathing and 7-day convenience.

Quick reference

Class & Role

Partial Opioid Agonist — Transdermal partial mu-opioid agonist.

Route / Formulation

Transdermal Patches (5, 10, 15, 20 mcg/hour). (Norspan)

Usual Dose & Max

Topical Apply one 5 mcg/hr patch. Change exactly every 7 DAYS. Rotate sites. Max 40 mcg/hour patch (2x 20mcg patches).

Key Indication Doses

Chronic / Osteoarthritis Pain: Topical Apply one 5 mcg/hr patch. Change exactly every 7 DAYS. Rotate sites. Renal Impairment: No dose adjustment required in severe CKD or dialysis.

Best Uses

Key Risks

Gastrointestinal: Nausea, constipation (significantly less than full agonists like Oxycodone). Dermatological: Severe erythema, pruritus, or blistering at the patch site. Cardiovascular: Mild QTc prolongation at max doses (rarely clinically relevant).

Key Interactions

Buprenorphine's extreme receptor affinity means it can physically block full agonists (like Oxycodone) from working if breakthrough pain occurs. However, at the low doses in Norspan patches (5-20 mcg/hr), this blockade is minimal and breakthrough PRN opioids usually still work fine.

Monitoring

Inspect the patch site. Write the date applied on the patch with a Sharpie. No specific routine laboratory tests required.

Clinical Pearl

Counsel the patient strictly: No hot water bottles, electric blankets, or saunas over the patch. The heat dilates skin capillaries, melting the drug reservoir directly into the blood and causing massive overdose.

Access

Authority requiredNorspan

Brand: Norspan
PBS status: Authority required

From this page

No calculator, monitoring schedule or factsheet is linked to this medicine page yet.